Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Acute Coronary Syndrome

Treatments: Drug: Rosuvastatin; Drug: Atorvastatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00296387

D3560L00052

CENTAURUS

Details and patient eligibility

About

The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.

Enrollment: 1,160 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospital admission for ACS with chest pain or discomfort occurring during rest or with minimal exertion,
• Percutaneous coronary intervention (PCI) planned,
• Evidence of coronary artery disease

Exclusion criteria

• Hypersensitivity to statins
• Any cholesterol lowering medication taken within 1 month prior V1
• Sustained ST-segment elevation on ECG

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind